{"nctId":"NCT02667444","briefTitle":"P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne","startDateStruct":{"date":"2016-02-19","type":"ACTUAL"},"conditions":["Acne Vulgaris"],"count":1330,"armGroups":[{"label":"SB204 4%","type":"EXPERIMENTAL","interventionNames":["Drug: SB204 4%"]},{"label":"Vehicle Gel","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle Gel"]}],"interventions":[{"name":"SB204 4%","otherNames":["NVN1000"]},{"name":"Vehicle Gel","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Moderate to severe acne\n* Minimum of 25 and no more than 70 non-inflammatory lesions (open and closed comedones) on the face\n* Minimum of 20 and no more than 40 inflammatory lesions (papules and pustules)\n\nExclusion Criteria:\n\n* Women of child-bearing potential who are pregnant, nursing, considering becoming pregnant\n* Any dermatologic condition that could interfere with clinical evaluations including severe, recalcitrant cystic acne","healthyVolunteers":false,"sex":"ALL","minimumAge":"9 Years","maximumAge":"99 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change From Baseline in Inflammatory Lesion Counts","description":"The absolute change from Baseline in inflammatory lesion counts was to be assessed on the face only (forehead, right and left cheeks, chin, and nose). Inflammatory lesions included papules, pustules, nodules, and cysts.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.1","spread":"10.27"},{"groupId":"OG001","value":"-10.9","spread":"10.81"}]}]}]},{"type":"PRIMARY","title":"Absolute Change From Baseline in Non-inflammatory Lesion Counts","description":"The absolute change from Baseline in non-inflammatory lesion counts was to be assessed on the face only (forehead, right and left cheeks, chin, and nose). Non-inflammatory lesions included open comedones (blackheads) and closed comedones (whiteheads).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.3","spread":"14.30"},{"groupId":"OG001","value":"-12.7","spread":"16.01"}]}]}]},{"type":"PRIMARY","title":"Proportion of Subjects With Investigator Global Assessment (IGA) Success at Week 12","description":"Proportion of subjects with Investigator Global Assessment (IGA) Success at Week 12 is defined as an IGA score of 0 or 1 (Clear/Almost Clear) and at least a 2 grade improvement from Baseline. The IGA scale is as follows:\n\nGrade Description 0 Clear: Clear skin with no inflammatory or non-inflammatory lesions.\n\n1. Almost clear: Rare non-inflammatory lesions with rare papules (papules may be resolving and hyperpigmented, though not pink-red).\n2. Mild: Some non-inflammatory lesions with no more than a few inflammatory lesions.\n3. Moderate: Up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than one nodulocystic lesion.\n4. Severe: Up to many non-inflammatory and inflammatory lesions, but no more than a few nodulocystic lesions","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Inflammatory Lesion Count","description":"The percent change from baseline in inflammatory lesion count","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.5","spread":"36.36"},{"groupId":"OG001","value":"-39.2","spread":"38.20"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Non-inflammatory Lesion Count","description":"The percent change from baseline in non-inflammatory lesion count","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.5","spread":"36.35"},{"groupId":"OG001","value":"-33.1","spread":"39.59"}]}]}]},{"type":"SECONDARY","title":"Time to Reduction in Inflammatory Lesion Count","description":"Median time to a 35% reduction (improvement) in inflammatory lesion count (Kaplan-Meier analysis)","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0","spread":null},{"groupId":"OG001","value":"56.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Improvement in IGA","description":"Median time to a 2 or more grade improvement in IGA (Kaplan-Meier analysis)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null},{"groupId":"OG001","value":"87.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":666},"commonTop":["Nasopharyngitis","Application site pain","Application site erythema","Headache"]}}}